Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...